The treatment of multiple orphan ophthalmic complexities for many years has been a matter that has eluded the knowledge of most of the top medical experts. However, Ophthotech Corp (NASDAQ:OPHT) has expressed that it is currently pursuing a very crucial strategy towards helping the ailing persons globally.
It hopes that soon it will succeed at leveraging its retina expertise and clinical experience for a better course. At the top of its priorities will be the coming up with therapies that will see it make a name in the large industry by providing top solutions.
Asides from this, the provider is also undertaking the age-related retinal programs. Its business development efforts are in a bid to access rights to some additional products, technologies as well as product candidates. It targets having in place everything it requires towards the treatment of ophthalmic diseases specifically those at the back of the eye.
The Chief Executive Officer and President of Ophthotech, Glenn P. Sblendorio opined, “We are excited to move the Company forward with a goal of becoming a leader in the development and commercialization of ophthalmic therapeutics for orphan diseases and for larger indications in the back of the eye.”
He added that as a company they remained much dedicated to bringing ophthalmic therapeutics to market. This company has plans underway to move on with its business development efforts. The main goal will be to broaden as well as advance its pipeline.
Ophthotech has the development of treatments for patients with devastating ophthalmic diseases at the center-stage of its diverse operations. The maximizing of value for its large number of shareholders is a commitment the company continues to fight for each and every passing day.
There is also the coming together of the provider and the Foundation Fighting Blindness in a progressive agreement. Ophthotech has urged FBB to serve it with information from its publicly available ProgStar study.
It intends to utilize that in designing its clinical trial of Zimura® for Stargardt disease. The rest of the orphan degenerative retinal programs of the company have also been quite wanting. They provider is also hoping for give that a major lift all the same.
